- Home
- IBO vs EVAX Comparison
IBO vs EVAX Comparison
Compare IBO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBO
- EVAX
- Stock Information
- Founded
- IBO 2018
- EVAX 2008
- Country
- IBO United States
- EVAX Denmark
- Employees
- IBO N/A
- EVAX N/A
- Industry
- IBO
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IBO
- EVAX Health Care
- Exchange
- IBO NYSE
- EVAX Nasdaq
- Market Cap
- IBO 16.5M
- EVAX 14.3M
- IPO Year
- IBO 2024
- EVAX 2021
- Fundamental
- Price
- IBO $2.60
- EVAX $1.68
- Analyst Decision
- IBO
- EVAX Strong Buy
- Analyst Count
- IBO 0
- EVAX 2
- Target Price
- IBO N/A
- EVAX $11.00
- AVG Volume (30 Days)
- IBO 64.6K
- EVAX 27.9K
- Earning Date
- IBO 11-12-2024
- EVAX 10-31-2024
- Dividend Yield
- IBO N/A
- EVAX N/A
- EPS Growth
- IBO N/A
- EVAX N/A
- EPS
- IBO 0.02
- EVAX N/A
- Revenue
- IBO N/A
- EVAX $3,295,000.00
- Revenue This Year
- IBO N/A
- EVAX $4,845.21
- Revenue Next Year
- IBO N/A
- EVAX $30.30
- P/E Ratio
- IBO $118.52
- EVAX N/A
- Revenue Growth
- IBO N/A
- EVAX N/A
- 52 Week Low
- IBO $1.22
- EVAX $1.59
- 52 Week High
- IBO $3.20
- EVAX $13.61
- Technical
- Relative Strength Index (RSI)
- IBO N/A
- EVAX 20.75
- Support Level
- IBO N/A
- EVAX $1.59
- Resistance Level
- IBO N/A
- EVAX $2.63
- Average True Range (ATR)
- IBO 0.00
- EVAX 0.23
- MACD
- IBO 0.00
- EVAX -0.09
- Stochastic Oscillator
- IBO 0.00
- EVAX 5.96
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.